DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea · Delayed Price · Currency is KRW 3,850.00
+5.00 (0.13%)
At close: Aug 3, 2026
DongKoo Bio & Pharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 104,112 | 147,920 | 131,049 | 156,349 | 169,609 | 232,556 | |
Market Cap Growth | -24.36% | 12.87% | -16.18% | -7.82% | -27.07% | -3.33% |
Enterprise Value | 191,455 | 232,426 | 172,921 | 172,036 | 175,056 | 221,869 |
Last Close Price | 3850.00 | 5470.00 | 4694.12 | 5398.48 | 5731.92 | 7541.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 2.18 | 2.94 | 64.38 | 13.24 | 25.64 | 24.94 |
PS Ratio | 0.43 | 0.61 | 0.53 | 0.73 | 0.87 | 1.50 |
PB Ratio | 0.70 | 0.97 | 1.24 | 1.42 | 1.66 | 2.32 |
P/TBV Ratio | 0.75 | 1.01 | 1.31 | 1.57 | 1.82 | 2.40 |
P/FCF Ratio | - | - | - | - | 14.32 | 17.05 |
P/OCF Ratio | 17.60 | - | 7.56 | 43.61 | 10.08 | 12.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.79 | 0.96 | 0.69 | 0.80 | 0.90 | 1.43 |
EV/EBITDA Ratio | 10.99 | 12.79 | 8.66 | 8.33 | 7.79 | 16.82 |
EV/EBIT Ratio | 21.95 | 25.13 | 13.63 | 11.77 | 10.40 | 27.26 |
EV/FCF Ratio | - | - | - | - | 14.78 | 16.27 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.86 | 0.85 | 0.82 | 0.40 | 0.34 | 0.24 |
Debt / EBITDA Ratio | 7.36 | 7.09 | 4.34 | 2.12 | 1.53 | 1.84 |
Debt / FCF Ratio | - | - | - | - | 2.90 | 1.78 |
Net Debt / Equity Ratio | 0.58 | 0.62 | 0.48 | 0.19 | -0.01 | -0.08 |
Net Debt / EBITDA Ratio | 4.99 | 5.15 | 2.52 | 1.01 | -0.04 | -0.59 |
Net Debt / FCF Ratio | -8.89 | -4.27 | -11.14 | -2.04 | -0.07 | -0.57 |
Asset Turnover | 0.82 | 0.84 | 1.15 | 1.19 | 1.19 | 1.04 |
Inventory Turnover | 2.09 | 2.05 | 2.20 | 2.26 | 2.74 | 2.52 |
Quick Ratio | 0.44 | 0.40 | 0.50 | 0.61 | 0.83 | 0.97 |
Current Ratio | 0.77 | 0.92 | 0.93 | 1.21 | 1.32 | 1.48 |
Return on Equity (ROE) | 40.16% | 38.95% | 1.84% | 11.11% | 6.54% | 9.58% |
Return on Assets (ROA) | 1.84% | 1.99% | 3.65% | 5.03% | 6.44% | 3.40% |
Return on Invested Capital (ROIC) | 2.95% | 3.76% | 4.61% | 10.07% | 14.53% | 7.40% |
Return on Capital Employed (ROCE) | 4.50% | 4.60% | 9.90% | 12.40% | 15.90% | 7.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 48.39% | 33.99% | 1.55% | 7.56% | 3.90% | 4.01% |
FCF Yield | -9.38% | -14.84% | -3.45% | -6.56% | 6.98% | 5.86% |
Payout Ratio | 6.44% | 6.46% | 162.74% | 25.72% | 42.39% | 10.11% |
Buyback Yield / Dilution | -5.42% | -3.59% | 1.74% | 0.48% | 1.78% | 0.12% |